Customise Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorised as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyse the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customised advertisements based on the pages you visited previously and to analyse the effectiveness of the ad campaigns.

No cookies to display.

DiabetologNytt Nr 1-2-2025
Senaste Nr DiabetologNytt i PDF
Arkiv alla nyheter

It’s Time to Move from the HbA1c to Better Metrics, Ambulatory Glucose Profile AGP, for Diabetes Control

Ambulatory Glucose Profiles includes four key metrics to improving glycemic control.

Although hemoglobin A1c (HbA1c) has been the gold standard metric for diabetes control since the landmark study, Diabetes Control and Complications Trial Study, it has its problems.

As the A1c is only an average of the preceding 120 days, it masks the occurrence and frequency of dangerous high and low blood glucose levels. For example, the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Trial reported that patients with an HbA1c level of 6.4% (comment DiabetologNytt: DCCT; Mono S Sweden 5.4% or IFCC 46 mmol/mol) spent nearly 100 minutes a day in the hypoglycemic range (<70 mg/dL; <2,9 mmol/l)).

Bergenstal et al has proposed a solution using a tool called the Ambulatory Glucose Profile (AGP) which incorporates four key metrics in guiding diabetes treatment including: time in range (TIR), glycemic variability (GV), glycemic exposure, and ranges for hypo- and hyperglycemia.

Despite the lack of a validated link between diabetes complications and time in a specified glycemic zone, TIR is an intuitive parameter that is also advocated by the Juvenile Diabetes Research Foundation. This parameter allows for interventions to assist in reducing hypoglycemic episodes.

GV is a reflection of both hyper- and hypoglycemic exposure. Although data is conflicting about the link between GV and diabetic complications, it is known that non-diabetic patients do not experience the variability in glucose ranges that are seen in diabetic patients.

Glycemic exposure represents mean and median glucose values and will allow insight to the effects of exercise, food, and insulin dosage.

Lastly, the ranges for hyper- and hypoglycemia will allow for standardization of care by assigning a low, medium, and high value for each glycemic state.

http://www.ncbi.nlm.nih.gov/pubmed/23451792  Aaron J. Kowalski and Sanjoy Dutta. Diabetes Technology & Therapeutics. March 2013, 15(3): 194-196. doi:10.1089/dia.2013.0060.

Diabetes Technol Ther. 2013 Mar;15(3):194-6. doi: 10.1089/dia.2013.0060. Epub 2013 Mar 1.


It’s Time to Move from the A1c to Better Metrics for Diabetes Control.
Kowalski AJ, Dutta S., Source, Juvenile Diabetes Research Foundation, New York, New York.

Nyhetsinfo

www red DiabetologNytt

Facebook
LinkedIn
Email
WhatsApp